Bright Minds Biosciences Inc. Condensed Interim Consolidated Financial Statements For the three and six months ended March 31, 2023 and 2022 (Expressed in Canadian Dollars) 1 | Page Bright Minds Biosciences Inc. Condensed Interim Consolidated Statements of Financial Position (Expressed in Canadian dollars) March 31, September 30, 2023 2022 As at Notes (unaudited) (audited) $ $ ASSETS Current Assets Cash and cash equivalents 9,672,160 11,627,913 Sales tax receivable 33,363 114,518 Other receivables - 41,261 ...

Bright Minds Biosciences Inc. Condensed Interim Consolidated Financial Statements For the three months ended December 31, 2022 and 2021 (Expressed in Canadian Dollars) 1 | Page Bright Minds Biosciences Inc. Condensed Interim Consolidated Statements of Financial Position (Expressed in Canadian dollars) December 31, September 30, 2022 2022 As at Notes (unaudited) (audited) $ $ ASSETS Current Assets Cash and cash equivalents 11,211,502 11,627,913 Sales tax receivable 59,275 114,518 Other receivables - 41,261 P ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of Each Class Trading Symbol(s) Name of each exchange on which registered Common Shares DRUG The Nasdaq Stock Market LLC FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) or 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURIT ...

Bright Minds Biosciences Inc. Condensed Interim Consolidated Financial Statements For the three and nine months ended June 30, 2022 and 2021 (Expressed in Canadian Dollars) Bright Minds Biosciences Inc. Condensed Interim Consolidated Statements of Financial Position (Expressed in Canadian dollars - Unaudited) | --- | --- | --- | --- | |------------------------------------------------------------|-------|--------------------|----------------------| | As at | Notes | June 30, 2022 | September 30, 2021 | | | | ...

Bright Minds Biosciences Inc. Condensed Interim Consolidated Financial Statements For the three and six months ended March 31, 2022 and 2021 (Expressed in Canadian Dollars) Bright Minds Biosciences Inc. Condensed Interim Consolidated Statements of Financial Position (Expressed in Canadian dollars - Unaudited) | --- | --- | --- | --- | |----------------------------------------------------|-------|--------------------|----------------------| | As at | Notes | March 31, 2022 | September 30, 2021 | | | | $ | $ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of Each Class Trading Symbol(s) Name of each exchange on which registered Common Shares DRUG The Nasdaq Stock Market LLC FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) or 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURIT ...